ClinicalTrials.gg
Not yet recruitingNCT07489599Updated Mar 24, 2026

A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

A Phase 1 interventional study of QLH2405 and QLH2405 in Alzheimer's Disease(AD) and Mild Cognitive Impairment (MCI), sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.

02

Conditions studied

  • Alzheimer's Disease(AD)
  • Mild Cognitive Impairment (MCI)
03

In context

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

This study's planned enrollment of 68 is close to the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Part A:

  1. Voluntarily participate and sign the .
  2. Male or female, aged 18 to 65 years (inclusive).
  3. Healthy status as confirmed by medical evaluation.
  4. (BMI) of 19-28 kg/m² (inclusive).
  5. Agree to use effective and have no plans for sperm/egg donation or pregnancy from ICF signing until 9 months post-dose.

Inclusion Criteria for Part B:

  1. Voluntarily participate and sign the informed consent, able to communicate well with the investigator and complete the trial per protocol.
  2. Male or female, aged 50 to 85 years (inclusive).
  3. A diagnosis of mild MCI due to AD or mild AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
  4. Has subjective cognitive and memory decline for ≥6 months.
  5. Confirmation of Alzheimer's disease pathological changes by amyloid PET (Aβ-PET) scan.
  6. Has one (or more) reliable study partner (s)/adult caregiver(s) can accompany the participant to all visits.
  7. Agree to use effective contraception and have no plans for sperm/egg donation or pregnancy from ICF signing until 9 months post-dose.

Exclusion Criteria for Part A:

  1. History of significant diseases, or any existing disease may affect the study or pose an unacceptable risk to the participant.
  2. Positive for , -Ab, Treponema pallidum antibody, or -Ab.
  3. History of blood donation, significant blood loss (total volume ≥400 mL), or blood transfusion within 3 months prior to screening.
  4. History of alcohol abuse within 1 year prior to screening; or positive alcohol breath test.
  5. History of drug abuse and/or substance abuse; or positive drug screening.
  6. Participation in any drug or medical device clinical trial within 3 months prior to screening.
  7. Pregnant or lactating women, or women of with a positiveβ-hCG test.
  8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.

Exclusion Criteria for Part B:

  1. Cognitive impairment or dementia caused by any disease other than AD.
  2. History of stroke within 6 months prior to screening, or imaging evidence of central nervous system diseases.
  3. History of epileptic seizures or epileptiform abnormalities on EEG within 6 months prior to screening.
  4. Unstable or severe diseases within 6 months prior to screening that, in the investigator's judgment, make the participant unsuitable for study participation.
  5. \<60 mL/min/1.73 m².
  6. or ALT >3 × (ULN), or total >2 × ULN.
  7. Current use or anticipated need during the study period for any medication prohibited by the study protocol.
  8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Part A Cohort 1: Dose level 1 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 1.

    Drug: QLH2405

  • Experimental
    Part A Cohort 2: Dose level 2 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 2.

    Drug: QLH2405

  • Placebo comparator
    Part A Cohort 2: Placebo

    Participants will receive a single dose of matching placebo to level 2.

    Drug: Placebo

  • Experimental
    Part A Cohort 3: Dose level 3 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 3.

    Drug: QLH2405

  • Placebo comparator
    Part A Cohort 3: Placebo

    Participants will receive a single dose of matching placebo to level 3.

    Drug: Placebo

  • Experimental
    Part A Cohort 4: Dose level 4 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 4.

    Drug: QLH2405

  • Placebo comparator
    Part A Cohort 4: Placebo

    Participants will receive a single dose of matching placebo to level 4.

    Drug: Placebo

  • Experimental
    Part A Cohort 5: Dose level 5 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 5.

    Drug: QLH2405

  • Placebo comparator
    Part A Cohort 5: Placebo

    Participants will receive a single dose of matching placebo to level 5.

    Drug: Placebo

  • Experimental
    Part A Cohort 6: Dose level 6 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 6.

    Drug: QLH2405

  • Placebo comparator
    Part A Cohort 6: Placebo

    Participants will receive a single dose of matching placebo to level 6.

    Drug: Placebo

  • Experimental
    Part B Cohort 1: Dose level 3 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 3.

    Drug: QLH2405

  • Placebo comparator
    Part B Cohort 1: Placebo

    Participants will receive a single dose of matching placebo to level 3.

    Drug: Placebo

  • Experimental
    Part B Cohort 2: Dose level 4 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 4.

    Drug: QLH2405

  • Placebo comparator
    Part B Cohort 2: Placebo

    Participants will receive a single dose of matching placebo to level 4.

    Drug: Placebo

  • Experimental
    Part B Cohort 3: Dose level 5 of QLH2405

    Participants will receive a single dose of QLH2405 at dose level 5.

    Drug: QLH2405

  • Placebo comparator
    Part B Cohort 3: Placebo

    Participants will receive a single dose of matching placebo to level 5.

    Drug: Placebo

Interventions

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugPlacebo

    QLH2405-matching placebo will be administered as specified in each treatment arm.

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugPlacebo

    QLH2405-matching placebo will be administered as specified in each treatment arm.

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugPlacebo

    QLH2405-matching placebo will be administered as specified in each treatment arm.

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugPlacebo

    QLH2405-matching placebo will be administered as specified in each treatment arm.

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugPlacebo

    QLH2405-matching placebo will be administered as specified in each treatment arm.

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugPlacebo

    QLH2405-matching placebo will be administered as specified in each treatment arm.

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugPlacebo

    QLH2405-matching placebo will be administered as specified in each treatment arm.

  • DrugQLH2405

    QLH2405 will be administered as specified in each treatment arm.

  • DrugPlacebo

    QLH2405-matching placebo will be administered as specified in each treatment arm.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    Percentage of Participants with AEs

    Time frame: Up to approximately 28 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 162 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 12 months is close to that.

Counting every sponsor, half of 235 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartEst.
Mar 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07489599
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Mar 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Fangyi Wang, Bachelor
Contact
fangyi.wang@qilu-pharma.com
+86-18266419923

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion